Archive
All News
Every briefing, headline, and filing we've published, newest first.
PeopleBriefing
Reports say President Trump may remove FDA Commissioner Marty Makary following internal turnover and disputes …
PolicyPharmaceutical Technology ↗
Japan’s latest NHI drug price revision for FY26 has now come into effect, with an average 4.02% drop in prices…
MoneyBioPharma Dive ↗
The Indianapolis-based company expanded its spend to ensure it can meet growing demand for its weight-loss dru…
DealsBioPharma Dive ↗
Deal volume in 2026 is substantially outpacing last year, and activity is being driven by interest in cancer a…
PolicyKFF Health News ↗
This issue brief provides background on the GENEROUS model, examines the factors that will contribute to the m…
DealsFiercePharma ↗
With an eye on the lucrative U.S. market, Italy’s Angelini Pharma will acquire rare disease specialist Catalys…
DealsFierceBiotech ↗
Roche is set to pay out a little more than $1 billion to acquire digital pathology specialist Path AI in a mov…
MoneyBriefing
The oral Wegovy launch brought $355M in its first quarter, helping Novo beat consensus despite insulin softnes…
The WeekDrug Channels ↗
Today's guest post comes from George Moore, Chief Product and Technology Officer at CareMetx. George argues th…
MoneyEndpoints News ↗
Odyssey Therapeutics pulled together $279 million from its initial public offering, the autoimmune disease dru…
MoneyBioPharma Dive ↗
Even though Elevidys beat Wall Street expectations, analysts expect investor focus to shift toward Sarepta's e…
PipelineEndpoints News ↗
Plus, news about BioCryst, GSK and Roche. 🙃 Entrada’s Duchenne drug disappoints: The biotech reported initial…
PolicySTAT News ↗
A political appointee gets in the way of a Sanofi drug's approval, and more from STAT's D.C. Diagnosis newslet…
MoneyPharmaVoice ↗
Sales and profit should shrink less than originally anticipated thanks to strong momentum for its new obesity …
DealsPharmaVoice ↗
Deal volume in 2026 is far outpacing last year, and is being driven by cancer and autoimmune disease drugs.…
PolicyFiercePharma ↗
Following a series of “most favored nation” pricing deals with 17 large pharma companies, the Trump administra…
DealsFierceBiotech ↗
GSK has found another potential way to treat cardiometabolic disease with a modality close to the pharma’s hea…
DealsBriefing
The $300M upfront deal gives Bayer control of PER-001, a midphase implant for glaucoma and diabetic retinopath…
DealsSTAT News ↗
The Italian firm Angelini Pharma is buying Catalyst Pharmaceuticals, the maker of rare disease drugs, for $4.1…
MoneyEndpoints News ↗
At least two drugmakers say they’re feeling the impact of the Inflation Reduction Act, after the first drug pr…
DealsEndpoints News ↗
Eli Lilly is committing to its roots, allocating $4.5 billion for new manufacturing investments across Indiana…
PolicyKFF Health News ↗
This page displays an interactive map of the current status of state decisions on the Affordable Care Act's Me…
DealsPharmaVoice ↗
Knoa Pharma will still sell the opioid medications that triggered a national crisis, but with guardrails.…
PolicyKFF Health News ↗
This brief reviews the case now before the Supreme Court, Louisiana v. FDA, and provides an overview of the ot…
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.